Die wichtigsten Arbeiten zu.....
Raltegravir (Isentress®)
#515 Sustained Antiretroviral Effect of Raltegravir at Week 156 in the BENCHMRK Studies and Exploratory Analysis of Late Outcomes based on Early Virologic Responses
Joseph Eron*1, D Cooper2, R Steigbigel3, B Clotet4, H Wan5, A Meibohm6, P Sklar5, B-Y Nguyen5, H Teppler5, and the BENCHMRK-1 and 2 Study Groups
1Univ of North Carolina at Chapel Hill, US; 2Univ of New South Wales, Sydney, Australia; 3State Univ of New York at Stony Brook, US; 4Hosp Germans Trias i Pujol, Barcelona, Spain; 5Merck Res Labs, North Wales, PA, US; and 6Statistical Consultant, Lafayette Hill, PA, US
#514 Sustained Antiretroviral Efficacy of Raltegravir after 192 Weeks of Combination ART in Treatment-Naive HIV-1 Infected Patients
Eduardo Gotuzzo*1, B-Y Nguyen2, M Markowitz3, F Mendo4, W Ratanasuwan5, C Lu2, J Zhao2, B Homony2, R Barnard2, H Teppler2, and the Protocol 004 Part II Study Team
1Hosp Nacionale Cayetano Heredia, Lima, Peru; 2Merck Res Labs, North Wales, PA, US; 3Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US; 4Hosp Nacionale Edgardo Rebagliati, Lima, Peru; and 5Sriraj Hosp, Bangkok, Thailand
#662 Hepatic Safety and Efficacy of Raltegravir in Patients Co-infected with HIV and HBV or HCV
Jurgen Rockstroh*1, H Teppler2, J Zhao2, P Sklar2, C Harvey2, R Leavitt2, and B-Y Nguyen2
#720 Metabolic Profiles and Body Composition Changes in Treatment-Naive HIV-Infected Patients Treated with Raltegravir 400 mg Twice-daily vs Efavirenz 600 mg Each bedtime Combination Therapy: 96-Week Follow-Up
Edwin DeJesus*1, C Cohen2, J Lennox3, A Lazzarin4, D Berger5, B Jin6, H Teppler6, B-Y Nguyen6, R Leavitt6, and P Sklar6
1Orlando Immunology Ctr, FL, US; 2Community Res Initiative of New England, Boston, MA, US; 3Emory Univ, Atlanta, GA, US; 4Univ Vita-Salute San Raffaele, Milan, Italy; 5Northstar Med Ctr, Chicago, IL, US; and 6Merck Res Labs, North Wales, PA, US
#557 Short -Term Raltegravir Monotherapy Does Not Predispose Patients to Develop RAL Resistance During Subsequent Combination Therapy: Analysis of Samples from Protocol 004
Michael Miller*, R Barnard, M Witmer, J Zhao, B-Y Nguyen, H Teppler, D Hazuda, and Protocol 004 Study Team
Merck & C
Kollegen Fragen
